A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Active, not recruiting · Phase 3 · NCT03589326
Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
At a glance
- Research payments reported, 2025
- $679,384
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 245
About the trial
- Sponsor
- Takeda
- Tested
- Ponatinib (drug), Imatinib (drug), Vincristine (drug), Dexamethasone (drug), Cytarabine (drug), Methotrexate (drug), Prednisone (drug)
- Dates
- Started 2018-10-04; completion 2027-07-31
- Results posted
- Yes
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.
From ClinicalTrials.gov, last updated 2025-11-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $679,384 in research payments for this study in 2025 (98 payments).
Products named: Iclusig
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Pankit J. Vachhani, MD Hematology & Oncology · Birmingham, AL
- Ibrahim T. Aldoss, M.D. Hematology · Duarte, CA
- Patricia A. Young, MD Medical Oncology · Los Angeles, CA
- Vamsi K. Kota, MD Hematology & Oncology · Augusta, GA
- Larry D. Cripe, MD Hematology & Oncology · Indianapolis, IN
- Bruce A. Chabner, MD Internal Medicine · Boston, MA
- Maria Baer, MD Hematology & Oncology · Baltimore, MD
- James K. Mccloskey II, M.D. Medical Oncology · Hackensack, NJ
- Bradley H. Goldberg, M.D. Hematology · Manhasset, NY
- Eunice Wang, MD Hematology & Oncology · Buffalo, NY
- Jessica T. Leonard, M.D. Hematology · Portland, OR
- Jose C. Cruz, MD Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Biomedical Research Alliance of New York LLC $205,550
- Ohsu Hospital and Clinics, OR $106,794
- Augusta University Research Institute Inc $87,155
- Hackensack University Medical Center, NJ $70,969
- University of Alabama Hospital, AL $55,897
- City of Hope National Medical Ctr $43,845
- University of Maryland Medical Center, MD $37,824
- University of California Davis Medical Center, CA $33,198
- Health Research Inc $14,797
- Indiana University Health, IN $13,180
- $5,150
- Sarah Cannon Research Institute LLC $4,276
- Massachusetts General Hospital, MA $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.